story of the week
Pembrolizumab vs Chemotherapy for Previously Untreated PD-L1–Expressing, Locally Advanced or Metastatic NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial
Lancet 2019 Apr 04;[EPub Ahead of Print], TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, V Srimuninnimit, KK Laktionov, I Bondarenko, K Kubota, GM Lubiniecki, J Zhang, D Kush, G LopesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.